ReviewThe oncologist2011
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.
Review in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.Pediatric blood & cancer · 2025Trial
- Case Report: Primary gallbladder undifferentiated small round cell sarcomas treated with gemcitabine, paclitaxel, bevacizumab and pembrolizumab achieved remarkable tumor regression.Frontiers in immunology · 2026Article
- Breaking the barrier: a guidelines-based review of antiangiogenesis drug resistance in pediatric cancer therapy.Clinical and experimental pediatrics · 2025Article
- Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy.International journal of molecular sciences · 2024Review
- A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.Pediatric blood & cancer · 2024Article
- A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- Targeting tumor microenvironment and metastasis in children with solid tumors.Current opinion in pediatrics · 2022Review
- Emerging and investigational therapies for neuroblastoma.Expert opinion on orphan drugs · 2017Article
- Safety of bevacizumab in patients younger than 4 years of age.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- The siRNA-Mediated Down-Regulation of Vascular Endothelial Growth Factor Receptor1.Iranian Red Crescent medical journal · 2016Article
- Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2.Cell journal · 2016Article
- Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Pediatric blood & cancer · 2015Article
- Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism · 2014Article
- Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Imaging in childhood cancer: a Society for Pediatric Radiology and Children's Oncology Group Joint Task Force report.Pediatric blood & cancer · 2013Review
- Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A.In silico pharmacology · 2013Article
- Aflibercept in pediatric solid tumors: moving beyond the trap.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis is a target shared by both adult epithelial cancers and the mesenchymal or embryonal tumors of childhood. Development of antiangiogenic agents for the pediatric population has been complicated by largely theoretical concern for toxicities specific to the growing child and prioritization among the many antiangiogenic agents being developed for adults. This review summarizes the mechanism of action and preclinical data relevant to childhood cancers and early-phase clinical trials in childhood solid tumors. Single-agent adverse event profiles in adults and children are reviewed with emphasis on cardiovascular, bone health, and endocrine side effects. In addition, pharmacological factors that may be relevant for prioritizing clinical trials of these agents in children are reviewed. Considerations for further clinical evaluation should include preclinical data, relative potency, efficacy in adults, and the current U.S. Food and Drug Administration approval status. Toxicity profiles of vascular endothelial growth factor (VEGF) signaling pathway inhibitors may be age dependent and ultimately, their utility in the treatment of childhood cancer will require combination with standard cytotoxic drugs or other molecularly targeted agents. In combination studies, toxicity profiles, potential drug interactions, and late effects must be considered. Studies to assess the long-term impact of VEGF signaling pathway inhibitors on cardiovascular, endocrine, and bone health in children with cancer are imperative if these agents are to be administered to growing children and adolescents with newly diagnosed cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.